News | February 25, 2011

Coronary Heart Disease Genetic Marker Test Cleared in Europe

February 25, 2011 – A diagnostic test used to help treat patients with high cholesterol received CE mark approval in Europe. The KIF6 genotyping assay, from Abbott, detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD). Often, statin treatment is being considered for these patients.

Previous research has shown that carriers of the KIF6 risk variant (60 percent of the population) have had significantly fewer fatal or nonfatal coronary events from statin therapy.

"The new pharmacogenetic KIF6 biomarker is very useful for my daily practice in cardiovascular risk factor management, particularly for patients with intermediate cardiovascular risk,” said Herbert Schuster, M.D. Ph.D., geneticist and preventive cardiologist, Berlin, Germany. “I use this marker to reclassify patients to further support individualized indication of statin therapy. In addition, carriers of the variant will significantly benefit from statin therapy and are more likely to benefit from continuous therapy."

In September 2010, Celera Corp. and Abbott announced a nonexclusive distribution agreement to market a CE-marked KIF6 diagnostic test for use on Abbott's m2000 instrument system. Under the agreement, Celera will manufacture the KIF6 test kit which Abbott Molecular will distribute in the European Union, other geographic areas that recognize the CE mark, and elsewhere worldwide, excluding the United States.

For more information:

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init